Search results for " Evans Blue"

showing 2 items of 2 documents

Neuroprotection by erythropoietin administration after experimental traumatic brain injury.

2007

A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several experimental models of brain and spinal cord injury. This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an indicator of brain edema, was measured with the wet-dry method and bl…

MaleTime FactorsBrain EdemaFunctional LateralityRats Sprague-Dawleychemistry.chemical_compoundTraumatic brain injuryMedicineAnalysis of Variance Animals Blood-Brain Barrier; drug effects Brain Edema; drug therapy/etiology Brain Infarction; drug therapy/etiology Brain Injuries; complications/drug therapy Disease Models; Animal Erythropoietin; administration /&/ dosage Evans Blue; diagnostic use Functional Laterality Humans Male Neurologic Examination Neuroprotective Agents; administration /&/ dosage Rats Rats; Sprague-Dawley Reaction Time; drug effects Recombinant Proteins Time Factorsadministration /&/ dosageSpinal cord injuryEvans BlueNeurologic ExaminationGeneral Neuroscienceexperimental models of brain and spinal cord injuryExtravasationNeuroprotectionRecombinant Proteinsmedicine.anatomical_structureNeuroprotective AgentsBlood-Brain BarrierAnesthesiadiagnostic usemedicine.drugEvans BlueBrain InfarctionTraumatic brain injuryCentral nervous systemrecombinant human EPO (rHuEPO)PlaceboNeuroprotectionReaction TimeAnimalsHumansMolecular BiologyErythropoietinAnalysis of VarianceNeuroscience (all)business.industryAnimaldrug therapy/etiologymedicine.diseaseRatsDisease Models AnimalchemistryErythropoietindrug effectsBrain InjuriesDisease Modelsrecombinant human EPO (rHuEPO); experimental models of brain and spinal cord injury; NeuroprotectionNeurology (clinical)Sprague-Dawleybusinesscomplications/drug therapyDevelopmental BiologyBrain research
researchProduct

NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhag…

2007

Increased levels of glutamate and aspartate have been detected after subarachnoid hemorrhage (SAH) that correlate with neurological status. The NMDA receptor antagonist felbamate (FBM; 2-phenyl-1,3-propanediol dicarbamate) is an anti-epileptic drug that elicits neuroprotective effects in different experimental models of hypoxia-ischemia. The aim of this dose-response study was to evaluate the effect of FBM after experimental SAH in rats on (1) behavioral deficits (employing a battery of assessment tasks days 1-5 post-injury) and (2) blood-brain barrier (BBB) permeability changes (quantifying microvascular alterations according to the extravasation of protein-bound Evans Blue by a spectropho…

Malemedicine.medical_specialtyExcitotoxicityPhenylcarbamatesBehavioral deficitsmedicine.disease_causeCisterna magnaBlood–brain barrierNeuroprotectionReceptors N-Methyl-D-AspartateFelbamateRats Sprague-Dawleychemistry.chemical_compoundInternal medicinemedicineAnimalsAnimals; Blood-Brain Barrier; Rats; Subarachnoid Hemorrhage; Evans Blue; Behavioral deficits; Cognitive deficits; NMDA receptor; FelbamatePostural BalanceEvans BlueBehavior AnimalDose-Response Relationship Drugbusiness.industryCognitive deficitsMicrocirculationBody WeightGlutamate receptorSubarachnoid HemorrhageNMDA receptorFelbamateRatsEndocrinologymedicine.anatomical_structureNeuroprotective AgentsSpectrometry FluorescencechemistryBlood-Brain BarrierPropylene GlycolsAnesthesiaCerebrovascular CirculationNMDA receptorNeurology (clinical)businessmedicine.drugEvans BlueJournal of neurotrauma
researchProduct